In general, genetic alterations that predict response to treatment account for approximately 30% of patients with NSCLC, including the mutations and/or rearrangements of EGFR, MET, BRAFV600E, ALK, ROS1, RET, and NTRK [109]. This evidence concerns the gene MET and non-small cell lung carcinoma.